DOCSLIB.ORG

Ibm Micromedex® Carenotes Titles by Category

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ibm Micromedex® Carenotes Titles by Category IBM MICROMEDEX® CARENOTES TITLES BY CATEGORY DECEMBER 2019 © Copyright IBM Corporation 2019 All company and product names mentioned are used for identification purposes only and may be trademarks of their respective owners. Table of Contents IBM Micromedex® CareNotes Titles by Category Allergy and Immunology ..................................................................................................................2 Ambulatory.......................................................................................................................................3 Bioterrorism ...................................................................................................................................18 Cardiology......................................................................................................................................18 Critical Care ...................................................................................................................................20 Dental Health .................................................................................................................................22 Dermatology ..................................................................................................................................23 Dietetics .........................................................................................................................................24 Endocrinology & Metabolic Disease ..............................................................................................26 Endocrinology ................................................................................................................................27 Environmental Health ....................................................................................................................27 Gastroenterology ...........................................................................................................................28 General Medicine...........................................................................................................................30 General Procedure ........................................................................................................................34 General Surgery ............................................................................................................................34 Gerentology ...................................................................................................................................34 Hematology....................................................................................................................................36 Hepatology.....................................................................................................................................38 Home Health Care .........................................................................................................................38 Infectious Disease .........................................................................................................................41 Laboratory Service.........................................................................................................................44 Medical Genetics ...........................................................................................................................44 Mental Health Services..................................................................................................................44 Neonatology...................................................................................................................................44 Nephrolology..................................................................................................................................46 Neurology ......................................................................................................................................46 Obstetrics/Gynecology...................................................................................................................49 Oncology........................................................................................................................................52 Ophthalmology...............................................................................................................................54 Orthopedics ...................................................................................................................................55 Otolarangology ..............................................................................................................................58 Pain Management..........................................................................................................................60 Pediatrics .......................................................................................................................................61 Physical Therapy ...........................................................................................................................68 Plastic Surgery...............................................................................................................................69 Preventative Care ..........................................................................................................................70 Primary Care..................................................................................................................................73 Psychiatry ......................................................................................................................................84 Public Health .................................................................................................................................86 Pulmonary Service ........................................................................................................................87 Pulmonology..................................................................................................................................87 Radiology.......................................................................................................................................88 Rehabilitation.................................................................................................................................90 Rheumatology ...............................................................................................................................92 Spinal Cord Injury Medicine...........................................................................................................92 Sports Medicine.............................................................................................................................93 Surgery ..........................................................................................................................................95 Thoracic Surgery ...........................................................................................................................99 Toxicology ...................................................................................................................................100 Transplant Medicine ....................................................................................................................100 Transplant Service.......................................................................................................................100 Trauma Service ...........................................................................................................................100 Trauma ........................................................................................................................................101 Urology ........................................................................................................................................103 Vascular Service..........................................................................................................................105 Vascular Surgery .........................................................................................................................105 Women's Health ..........................................................................................................................106 Lab Titles Lab Titles .....................................................................................................................................109 Medication Titles and Medication Essential Fact Sheets Medication Titles..........................................................................................................................115 IBM Micromedex® CareNotes Titles by Category IBM Micromedex® Patient Education, featuring IBM Micromedex® CareNotes, covers the continuum of care from pre-care, inpatient, and discharge instructions to emergency department and ambulatory education, including topics ranging from disease and procedure to medication education, providing patient-specific education that supports regulatory objectives and improves outcomes. CareNotes delivers a single source of evidence-based patient education materials. These robust documents and tools provide patient-specific information at every stage of care — pre-care, inpatient care, lab tests, continuing care, discharge instructions, drug information, and emergency department education. From EHR certified technology
Load more

Recommended publications
  • Oxygen and Oxygen Equipment Local Coverage Determination (LCD)
    Local Coverage Determination (LCD): Oxygen and Oxygen Equipment (L33797) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR NAME CONTRACT TYPE CONTRACT JURISDICTION STATE(S) NUMBER CGS Administrators, LLC DME MAC 17013 - DME MAC J-B Illinois Indiana Kentucky Michigan Minnesota Ohio Wisconsin CGS Administrators, LLC DME MAC 18003 - DME MAC J-C Alabama Arkansas Colorado Florida Georgia Louisiana Mississippi New Mexico North Carolina Oklahoma Puerto Rico South Carolina Tennessee Texas Virgin Islands Virginia West Virginia Noridian Healthcare Solutions, DME MAC 16013 - DME MAC J-A Connecticut LLC Delaware District of Columbia Maine Maryland Massachusetts New Hampshire New Jersey New York - Entire State Pennsylvania Rhode Island Vermont CONTRACTOR NAME CONTRACT TYPE CONTRACT JURISDICTION STATE(S) NUMBER Noridian Healthcare Solutions, DME MAC 19003 - DME MAC J-D Alaska LLC American Samoa Arizona California - Entire State Guam Hawaii Idaho Iowa Kansas Missouri - Entire State Montana Nebraska Nevada North Dakota Northern Mariana Islands Oregon South Dakota Utah Washington Wyoming LCD Information Document Information LCD ID Original Effective Date L33797 For services performed on or after 10/01/2015 LCD Title Revision Effective Date Oxygen and Oxygen Equipment For services performed on or after 08/02/2020 Proposed LCD in Comment Period Revision Ending Date N/A N/A Source Proposed LCD Retirement Date DL33797 N/A AMA CPT / ADA CDT / AHA NUBC Copyright Notice Period Start Date Statement 06/18/2020 CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Notice Period End Date Reserved.
    [Show full text]
  • Breastfeeding Complications (Women) 2001.04
    05/2015 602 Breastfeeding Complications or Potential Complications (Women) Definition/Cut-off Value A breastfeeding woman with any of the following complications or potential complications for breastfeeding: Complications (or Potential Complications) Severe breast engorgement Cracked, bleeding or severely sore nipples Recurrent plugged ducts Age ≥ 40 years Mastitis (fever or flu-like symptoms with localized Failure of milk to come in by 4 days postpartum breast tenderness) Tandem nursing (breastfeeding two siblings who are Flat or inverted nipples not twins) Participant Category and Priority Level Category Priority Pregnant Women 1 Breastfeeding Women 1 Justification Severe breast engorgement Severe breast engorgement is often caused by infrequent nursing and/or ineffective removal of milk. This severe breast congestion causes the nipple-areola area to become flattened and tense, making it difficult for the baby to latch-on correctly. The result can be sore, damaged nipples and poor milk transfer during feeding attempts. This ultimately results in diminished milk supply. When the infant is unable to latch-on or nurse effectively, alternative methods of milk expression are necessary, such as using an electric breast pump. Recurrent plugged ducts A clogged duct is a temporary back-up of milk that occurs when one or more of the lobes of the breast do not drain well. This usually results from incomplete emptying of milk. Counseling on feeding frequency or method or advising against wearing an overly tight bra or clothing can assist. Mastitis Mastitis is a breast infection that causes a flu-like illness accompanied by an inflamed, painful area of the breast - putting both the health of the mother and successful breastfeeding at risk.
    [Show full text]
  • Chronic Cough, Shortness of Breathe, Wheezing? What You Should
    CHRONIC COUGH, SHORTNESS OF BREATH, WHEEZING? WHAT YOU SHOULD KNOW ABOUT COPD. A quick guide on Chronic Obstructive Pulmonary Disease COPD.nhlbi.nih.gov COPD, or chronic obstructive Most often, COPD occurs in people pulmonary disease, is a serious lung age 40 and over who… disease that over time makes it hard • Have a history of smoking to breathe. Other names for COPD include • Have had long-term exposure to lung irritants chronic bronchitis or emphysema. such as air pollution, chemical fumes, or dust from the environment or workplace COPD, a leading cause of death, • Have a rare genetic condition called alpha-1 affects millions of Americans and causes antitrypsin (AAT) deficiency long-term disability. • Have a combination of any of the above MAJOR COPD RISK FACTORS history of SMOKING AGE 40+ RARE GENETIC CONDITION alpha-1 antitrypsin (AAT) deficiency LONG-TERM exposure to lung irritants WHAT IS COPD? To understand what COPD is, we first The airways and air sacs are elastic (stretchy). need to understand how respiration When breathing in, each air sac fills up with air like and the lungs work: a small balloon. When breathing out, the air sacs deflate and the air goes out. When air is breathed in, it goes down the windpipe into tubes in the lungs called bronchial In COPD, less air flows in and out of tubes or airways. Within the lungs, bronchial the airways because of one or more tubes branch into thousands of smaller, thinner of the following: tubes called bronchioles. These tubes end in • The airways and air sacs lose bunches of tiny round air sacs called alveoli.
    [Show full text]
  • Investigating the Effect of Non-Pharmacological Treatments
    http:// ijp.mums.ac.ir Review Article (Pages: 11041-11047) Investigating the Effect of Non-Pharmacological Treatments on Reduction of Breast Engorgement in Breastfeeding Women: A Review Study Parisa Razmjouei1, Sara Khashkhashi Moghaddam2, Omolbanin Heydari3, Behnoush Mehdizadeh4, Malihe Pouredalati3, Mohammad Tabarestani5, Zahra Ramazanian Bafghi3, Roozbeh Nasibeh6, *Somayeh Moeindarbary71 1Shahid Faghihi Hospital, Department of Gynecology and Obstetrics, Shiraz University of Medical Sciences, Shiraz, Iran. 2Anesthesiologist, Department of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran. 3Students Research Committee, Razi School of Nursing and Midwifery, Kerman University of Medical Sciences, Kerman, Iran. 4Department of Pathology, Mashhad University Of Medical Science, Mashhad, Iran. 5Medical Student, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran. 6Mother and Child Welfare Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 7Assistant Professor, Department of Obstetrics and Gynecology, Neonatal and Maternal Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Abstract Background: Breast engorgement is a common postpartum problem that has been identified as the third maternal factor that leads to a decrease or discontinuation of breastfeeding and breast abscess. Considering the side effects of chemical drugs during lactation, the aim of the present review study was to investigate the effect of non-pharmacological treatments on reduction
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use BENZHYDROCODONE and ACETAMINOPHEN TABLETS Safely and Effectively
    BENZHYDROCODONE AND ACETAMINOPHEN- benzhydrocodone and acetaminophen tablet KVK-Tech, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BENZHYDROCODONE AND ACETAMINOPHEN TABLETS safely and effectively. See full prescribing information for BENZHYDROCODONE AND ACETAMINOPHEN TABLETS. BENZHYDROCODONE AND ACETAMINOPHEN tablets, for oral use, CII Initial U.S. Approval: 1982 WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE- THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS See full prescribing information for complete boxed warning. Benzhydrocodone and Acetaminophen tablets exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions. (5.1) To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products. (5.2) Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. (5.3) Accidental ingestion of Benzhydrocodone and Acetaminophen tablets, especially by children, can result in a fatal overdose of hydrocodone. (5.3) Prolonged use of Benzhydrocodone and Acetaminophen tablets during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
    [Show full text]
  • Download Book
    Methods in Molecular Biology 2000 Volkmar Weissig Tamer Elbayoumi Editors Pharmaceutical Nanotechnology Basic Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Pharmaceutical Nanotechnology Basic Protocols Edited by Volkmar Weissig and Tamer Elbayoumi Department of Pharmaceutical Sciences, College of Pharmacy, Midwestern University, Glendale, AZ, USA Nanomedicine Center of Excellence in Translational Cancer Research, Midwestern University, Glendale, AZ, USA Editors Volkmar Weissig Tamer Elbayoumi Department of Pharmaceutical Sciences Department of Pharmaceutical Sciences College of Pharmacy, Midwestern University College of Pharmacy, Midwestern University Glendale, AZ, USA Glendale, AZ, USA Nanomedicine Center of Excellence Nanomedicine Center of Excellence in Translational Cancer Research in Translational Cancer Research Midwestern University Midwestern University Glendale, AZ, USA Glendale, AZ, USA ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-9515-8 ISBN 978-1-4939-9516-5 (eBook) https://doi.org/10.1007/978-1-4939-9516-5 © Springer Science+Business Media, LLC, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • ANTHRASIL™ Safely and Effectively
    53 Weight-based Pediatric Dose Body Weight Vials per Dosea Body Weight Vials per Dose (kg) (kg) 1 HIGHLIGHTS OF PRESCRIBING INFORMATION <5 1 25 to <35 4 <10 1 35 to <50 5 10 to <18 2 50 to <60 6 These highlights do not include all the information needed to use 2 18 to <25 3 ≥60 7 ANTHRASIL™ safely and effectively. See full prescribing information for 3 aSelect initial dose based on clinical severity. Dose may be doubled for severe ANTHRASIL. 4 cases in patients >5 kg. 5 ANTHRASIL [Anthrax Immune Globulin Intravenous (Human)], sterile 54 6 Administer ANTHRASIL by slow intravenous infusion using an infusion solution for infusion 55 7 pump (maximum 2 mL per minute). 56 8 Initial U.S. Approval: March 24, 2015 57 9 ---------------------DOSAGE FORMS AND STRENGTHS---------------------- 10 58 59 Each single-use vial contains a minimum potency of ≥60 units by Toxin 11 WARNING: INTERACTIONS WITH GLUCOSE MONITORING 60 Neutralization Assay (TNA) (3). 12 SYSTEMS AND THROMBOSIS 61 13 See full prescribing information for complete boxed warning. 62 -------------------------------CONTRAINDICATIONS------------------------------ 14 • Maltose in immune globulin products, including ANTHRASIL, may give 63 • History of anaphylactic or severe systemic reaction to human immune 15 falsely high blood glucose levels with some blood point-of-care glucose 64 globulins (4) 16 testing systems (for example those based on the GDH-PQQ or glucose-dye- 65 • IgA deficiency with antibodies against IgA and a history of IgA 17 oxidoreductase methods) resulting in inappropriate administration of insulin 66 hypersensitivity (4) 18 and life-threatening hypoglycemia. To avoid interference by maltose 67 19 contained in ANTHRASIL, perform blood glucose measurements in patients 68 -----------------------WARNINGS AND PRECAUTIONS------------------------ 20 receiving ANTHRASIL with a glucose-specific method (monitor and test 21 strips).
    [Show full text]
  • Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Drug Use Evaluation: Antipsychotic Utilization in Schizophrenia Patients Research Questions: 1. How many schizophrenia patients are prescribed recommended first-line second-generation treatments for schizophrenia? 2. How many schizophrenia patients switch to an injectable antipsychotic after stabilization on an oral antipsychotic? 3. How many schizophrenia patients are prescribed 2 or more concomitant antipsychotics? 4. Are claims for long-acting injectable antipsychotics primarily billed as pharmacy or physician administered claims? 5. Does adherence to antipsychotic therapy differ between patients with claims for different routes of administration (oral vs. long-acting injectable)? Conclusions: In total, 4663 schizophrenia patients met inclusion criteria, and approximately 14% of patients (n=685) were identified as treatment naïve without claims for antipsychotics in the year before their first antipsychotic prescription. Approximately 45% of patients identified as treatment naïve had a history of remote antipsychotic use, but it is unclear if antipsychotics were historically prescribed for schizophrenia. Oral second-generation antipsychotics which are recommended as first-line treatment in the MHCAG schizophrenia algorithm were prescribed as initial treatment in 37% of treatment naive patients and 28% of all schizophrenia patients. Recommended agents include risperidone, paliperidone, and aripiprazole. Utilization of parenteral antipsychotics was limited in patients with schizophrenia. Overall only 8% of patients switched from an oral to an injectable therapy within 6 months of their first claim. Approximately, 60% of all schizophrenia patients (n=2512) had claims for a single antipsychotic for at least 12 continuous weeks and may be eligible to transition to a long-acting injectable antipsychotic.
    [Show full text]
  • Doxapram Shortens Recovery Following Sevoflurane Anesthesia [Le Doxapram Hâte La Récupération Après Une Anesthésie Au Sévoflurane]
    456 CANADIAN JOURNALGENERAL OF ANESTHESIA ANESTHESIA Doxapram shortens recovery following sevoflurane anesthesia [Le doxapram hâte la récupération après une anesthésie au sévoflurane] Chi-Chen Wu MD,* Martin S. Mok MD,* Jui-Yuan Chen MD,† Gong-Jhe Wu MD,† Yeong-Ray Wen MD,† Chao-Shun Lin MD* Purpose: A randomized, double blind controlled trial was possibilité de serrer la main sur demande, le temps d’extubation et undertaken to investigate the effect of doxapram on recovery le score de récupération d’Aldrete. Les valeurs de l’index bispectral, times and bispectral index following sevoflurane anesthesia. la tension artérielle systolique et la fréquence cardiaque ont été Methods: Upon completion of surgery under sevoflurane anes- enregistrées avant l’anesthésie, pendant l’opération et à chaque thesia, 60 adult patients were randomly allocated to receive minute pendant 15 min après l’administration du médicament. either doxapram hydrochloride 1 mg·kg–1 iv or saline placebo. Résultats : Le temps écoulé avant l’ouverture des yeux a été plus Clinical recovery from anesthesia was assessed by time to eye court avec le doxapram qu’avec le placebo (6,9 ± 2,2 min vs 9,9 opening on verbal command, hand squeezing on command, ± 3,1 min, P < 0,05). Les scores moyens de l’index bispectral ont time to extubation, and the Aldrete recovery score. Bispectral été aussi plus élevés avec le doxapram sept à huit minutes après index values, systolic blood pressure, and heart rate were l’administration du médicament expérimental (P < 0,05). Un recorded at baseline (before anesthesia), during surgery, and retour à la conscience plus rapide a été associé à une plus grande every minute for 15 min after administration of the study drug.
    [Show full text]
  • Type 1 Diabetes and Pregnancy
    Type 1 diabetes and pregnancy Information for patients 1 2 Contents How will diabetes affect my pregnancy? 4 How will diabetes affect my baby? 5 My antenatal care 6 Hypoglycaemia 9 Planning for your birth 12 After your baby is born 15 Nutrition and related issues 17 Diet and lifestyle Controlling your blood glucose levels with diet Fluid intake Fat in foods Calcium Iron Folic acid and diabetes Diabetic products Symptoms in pregnancy How much weight should I expect to put on? Physical activity Suitable snacks Additional information Breastfeeding and diabetes 31 What happens once my baby is born? 34 For the future 37 References and useful links 39 3 This booklet aims to tell you what care to expect during and after your pregnancy when you have diabetes. It will not answer every question you may have, so please write any concerns down and ask your midwife or doctor. We run a joint antenatal and diabetes clinic at Barnet Hospital and the Royal Free Hospital. We have a dedicated multidisciplinary team who will review you on a regular basis to provide advice and support throughout your pregnancy. The team consists of a consultant endocrinologist, obstetrician, diabetes specialist midwife, diabetes specialist nurse and a diabetes specialist dietitian. How will diabetes affect my pregnancy? With good pre-conception care and good diabetes control there is every chance of a successful pregnancy. As soon as your pregnancy is confirmed, you should attend the joint diabetes antenatal clinic. Here you will receive support and advice to enable you to obtain and maintain good control of your diabetes as early in your pregnancy as possible.
    [Show full text]